Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Marten Falkenberg , Joakim Nordanstig Added: 8 months ago
ESC Congress 2025 - Paclitaxel-coated devices in critical limb threatening ischemia were not effective in preventing amputation, nor improving quality-of-life in intermittent claudication.Dr Mårten Falkenberg (Sahlgrenska University Hospital, Gothenburg, SE) and Prof Joakim Nordanstig (Sahlgrenska University Hospital, Gothenburg, SE) join us to discuss findings from the SWEDEPAD 1 and 2 parallel… View more
Author(s): Harriette Van Spall , Marc P Bonaca Added: 1 year ago
ACC 25 - STRIDE shows subcutaneous semaglutide improved walking ability and related quality of life in patients with both type 2 diabetes and peripheral arterial disease (PAD) with intermittent claudication symptoms.Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Marc Bonaca (University of Colorado School of Medicine, Aurora, CO, US) to discuss the… View more
Author(s): Marc P Bonaca Added: 1 year ago
AHA Conference 2024 - New insights from the CLEAR OUTCOMES trial investigating bempedoic acid (Esperion Therapeutics Inc.) in statin-intolerant patients with peripheral arterial disease (PAD).Dr Marc Bonaca (University of Colorado School of Medicine, Colorado, US) joins us onsite at AHA Conference to discuss new insights from CLEAR OUTCOMES (NCT02993406).CLEAR OUTCOMES is a double-blind,… View more
Author(s): Subodh Verma Added: 8 months ago
ESC Congress 2025 - New findings from STRIDE further demonstrate effectiveness of semaglutide in improving functional outcomes in PAD.Dr Subodh Verma joins us to discuss new findings from the STRIDE study, which investigated semaglutide 1.0mg in individuals with peripheral artery disease (PAD). 792 participants were enrolled in the trial, 24.6% of which were female, and 75.4% male.Findings showed… View more
Author(s): Added: 10 months ago
ADA 2025 - We are joined by Dr Alice Cheng (University of Toronto, Toronto, CA) to discuss the clinical implications of STRIDE (NCT04560998). The placebo-controlled study investigated whether semaglutide with standard-of-care treatment has an effect on walking ability in patients with PAD and T2D. The primary outcome measure was the change in maximum walking distance on a constant load treadmill… View more
Dr McDermott has devoted her career to advancing our understanding of peripheral artery disease (PAD), making significant contributions to medical knowledge in this field. As the Jeremiah Stamler Professor of Medicine and a professor of preventive medicine in epidemiology at Northwestern University’s Feinberg School of Medicine, she is a board-certified general internal medicine physician and a… View more
Author(s): Ulf Teichgräber Added: 1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of the trial shows that percutaneous transluminal angioplasty (PTA) with the sirolimus drug coated balloon (DCB) in patients with femoropopliteal artery disease was/was not noninferior to PTA with the paclitaxel DCB.Prof Ulf Teichgräber joins us onsite at TCT Conference to discuss the findings from the sirolimus- vs. paclitaxel-coated balloon… View more